(IN BRIEF) Researchers at Newcastle University have discovered a new biological mechanism explaining why some patients do not respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors. They identified T regulatory cells (Tregs) as key drivers of ICB … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged anti-CD30, Brentuximab Vedotin, Cancer Immunotherapy, cancer research, combination treatment, ICB resistance, immune checkpoint blockade, immunotherapy breakthroughs, lung cancer, melanoma, metastatic cancer, Newcastle University, pancreatic cancer, PD-1, skin cancer, solid tumors, T regulatory cells
(IN BRIEF) The University of Exeter has developed a new algorithm for interpreting blood test results, helping GPs detect potential cancer warning signs earlier, particularly through variations in platelet count. The Royal Devon University Healthcare NHS Foundation Trust is the … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged algorithm, Australia, blood test, bowel cancer, CANADA, Cancer Detection, Cancers journal, David Walton, Devon, early diagnosis, early warning signs, England, Exeter HealthTech Research Centre, general practitioners, GP, High or Elevated Level of Platelets (HELP) Flag, lung cancer, medical research, National Institute for Health and Care Research, NHS, patient outcomes, personalized thresholds, platelet count, platelet variation, Professor Sarah Bailey, RDUH, Royal Devon University Healthcare NHS Foundation Trust, University of Exeter
(IN BRIEF) In early 2024, Europe’s medical and research communities announced major breakthroughs in cancer care, highlighting new treatments like AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for lung and breast cancer, and AstraZeneca’s Tagrisso for EGFR-mutated lung cancer. Diagnostic advancements … Read the full press release
Posted in Finland, Germany, Healthcare, Insurance, News, Pharma & Biotech, Science, Society, Switzerland, Technology, United Kingdom
Tagged accessible cancer solutions, AstraZeneca, Aviva, BioNTech, breast cancer, breast cancer screening, cancer care, cancer diagnostics, cancer prevention awareness, cancer research, cancer treatment, colorectal cancer, Daiichi Sankyo, datopotamab deruxtecan, Duality Biologics, Eckert & Ziegler, EMA, FDA, genetic risk information, Inspirna, lung cancer, Merck KGaA, multi-cancer early detection, neuroendocrine neoplasms diagnostics, Novartis, ompenaclid, oncology, polygenic risk score, preventive healthcare, Professor Tim Maughan, ReSisTrace methodology, Stage III EGFR-mutated lung cancer, Swiss Re Institute, Tagrisso, treatment-resistant cancer cells, University of Helsinki, University of Liverpool
(IN BRIEF) AstraZeneca and Daiichi Sankyo have received European Union (EU) approval for their drug Enhertu as a monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) in adult patients with activating HER2 mutations who require systemic therapy … Read the full press release
Posted in Business, Environment, European Union, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, Daiichi Sankyo, Dave Fredrickson, Enhertu, EU approval, HER2-Mutant, Ken Keller, lung cancer, Martin Reck, monotherapy, NSCLC, partnership, sustainability
(IN BRIEF) AstraZeneca’s supplemental New Drug Application (sNDA) for Tagrisso (osimertinib) in combination with chemotherapy has been granted Priority Review by the US Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic epidermal … Read the full press release
Posted in Business, Education, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, chemotherapy, EGFR, FLAURA2, lung cancer, osimertinib, Susan Galbraith, Tagrisso, Treatment USA
(IN BRIEF) AstraZeneca has unveiled data from four pivotal Phase III trials at the European Society for Medical Oncology (ESMO) Congress, demonstrating advances in cancer treatments across multiple types of cancers. These trials include TROPION-Lung01 and TROPION-Breast01, showcasing the significance … Read the full press release
Posted in Business, Education, Healthcare, Industrial, Management, Media, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, breast cancer, cancer treatments, datopotamab deruxtecan, Dave Fredrickson, DESTINY-PanTumor02, DUO-E, ESMO Congress, FLAURA2, gastrointestinal cancer, Imfinzi, lung cancer, MATTERHORN, Phase III Trials, Susan Galbraith, Tagrisso, TROPION-Breast01, TROPION-Lung01
(IN BRIEF) Researchers at the University of Liverpool, in collaboration with Janssen Pharmaceutica, have made significant progress in using blood proteins to predict future lung cancer. The study analyzed blood samples taken from healthy participants up to ten years before … Read the full press release
(IN BRIEF) AstraZeneca will showcase new data from its industry-leading Oncology pipeline and portfolio at the American Association for Cancer Research Annual Meeting. A total of 70 presentations will be given, including a plenary presentation on the AEGEAN Phase III … Read the full press release
Posted in Business, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, United Kingdom
Tagged AstraZeneca, AZD5335, AZD9592, early-stage, Imfinzi, lung cancer, oncology, Susan Galbraith, treatment
Application is being reviewed under the US FDA’s Real-Time Oncology Review pilot programme Based on results of the Phase III IMpower010 study, presented at ASCO, that showed adjuvant Tecentriq improved disease-free survival by more than one-third in PD-L1-positive early-stage lung cancer, compared with … Read the full press release
Posted in Healthcare, Marketing, News, Pharma & Biotech, Switzerland
Tagged atezolizumab, Cancer Immunotherapy, chemotherapy, FDA, Levi Garraway, lung cancer, non-small cell lung cancer, NSCLC, Real-Time Oncology Review, Roche, sBLA, supplemental Biologics License Application, Tecentriq®, treatment, tumours
(PRESS RELEASE) FREIBURG, Germany, 1-Jul-2021 — /EuropaWire/ — Prostate cancer is the second most common cancer. According to the American Cancer Association, 1 in every 8 men will be diagnosed with it in their lifetime. In 2018 around 1.2 million … Read the full press release
Posted in Business, Germany, Healthcare, Investment, News, Pharma & Biotech, Science
Tagged American Cancer Association, B66, bioscience, Biotech, bladder, breast, Cancer, colorectal, Dr Eric Metzger, Freiburg, Germany, histone methyltransferase, inhibitors, KMT9, lung cancer, Manfred Jung, Mike Dunckley, pharma, Professor Manfred Jung, Professor Roland Schule, Professors Roland Schule, prostate cancer, prostate tumours, University of Freiburg
(PRESS RELEASE) CAMBRIDGE, 20-Nov-2020 — /EuropaWire/ — AstraZeneca (LON: AZN), a global, science-led biopharmaceutical company, has announced the US Food and Drug Administration (FDA) approval of its Imfinzi (durvalumab) for an additional dosing option, a 1,500mg fixed dose every four … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged bladder cancer, Dave Fredrickson, Imfinzi, Io, lung cancer, NSCLC, oncology, SCLC, Small cell lung cancer, Victoria M. Villaflor MD
uPath PD-L1 (SP263) image analysis uses automated pre-computing and one-click scoring to enable quicker and accurate detection and measurement of tumour cell staining positivity Roche advances personalised healthcare with development of image analysis algorithms using artificial intelligence Faster, more accurate … Read the full press release
First clinical data from tiragolumab, Roche’s novel anti-TIGIT cancer immunotherapy, in combination with Tecentriq® (atezolizumab) in patients with PD-L1-positive metastatic non-small cell lung cancer (NSCLC) Updated overall survival data for Alecensa® (alectinib), in people living with anaplastic lymphoma kinase (ALK)-positive … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Switzerland
Tagged Alecensa®, alectinib, anaplastic lymphoma kinase, ASCO virtual newsroom, ASCO20 Virtual Scientific Program, atezolizumab, cancer care, Cancer Immunotherapy, clinical data tiragolumab, Levi Garraway M.D. Ph.D., lung cancer, Roche, Tecentriq®
This year’s Swiss Aerosol Award goes to Maria Muñoz. The Empa researcher investigated the emission behavior of so-called GDI engines (gasoline-direct injection). Her results are alarming: GDI vehicles emit up to 17 times more carcinogenic substances than modern diesel vehicles. … Read the full press release
BASEL, 20-Mar-2018 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane [albumin-bound … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged atezolizumab, Cancer, chemotherapy, lung, lung cancer, lungcancer, Roche, Sandra Horning, squamous
Imfinzi is the only immunotherapy approved for patients with unresectable Stage III non-small cell lung cancer Imfinzi showed an 11.2 month improvement in median progression-free survival (16.8 months compared to 5.6 months on placebo) CAMBRIDGE, 22-Feb-2018 — /EuropaWire/ — AstraZeneca and … Read the full press release
Posted in Healthcare, Pharma & Biotech, United Kingdom
Tagged AstraZeneca, Cancer, chemotherapy, Dave Fredrickson, Imfinzi, lung, lung cancer, lungcancer, MedImmune, radiation therapy, Scott J. Antonia MD Ph.D.
Review of blinded, pre-planned oncology safety analyses revealed a 77% reduction in lung cancer mortality and 67% reduction in lung cancer cases in patients treated with 300mg of ACZ885 CANTOS is the first Phase III clinical trial to support a … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged ACZ885, CANTOS, lung cancer, Novartis
NAVIGATE Study Assesses Impact of Minimally Invasive Technology to Aid in Early Diagnosis and Treatment of Lung Cancer DUBLIN, 14-Mar-2016 — /EuropaWire/ — Committed to technologies that assist in the goal of reducing lung cancer morbidity worldwide, Medtronic (NYSE: MDT) today … Read the full press release
Posted in Healthcare, Ireland, Pharma & Biotech
Tagged lung cancer, Mag. Petra Lichtenberger, Medtronic, NAVIGATE clinical trial, Vafa Jamali
• Results of global Phase IIb LUX-Lung 7 trial demonstrate afatinib superior in reducing the risk of lung cancer progression and the risk of treatment failure both by 27% compared to gefitinib1 • More patients on afatinib were free of … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech
BASEL, 14-12-2015 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) granted accelerated approval to Alecensa® (alectinib) for the treatment of people with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer … Read the full press release
Posted in Government, Healthcare, Pharma & Biotech, Switzerland
Tagged lung cancer, Roche’s Alecensa®, US FDA
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?